Risk factor
Very high price volatility
Profitability factor
Very favourable analyst view
About
Cynata Therapeutics Limited, together with its subsidiaries, develops and commercializes a proprietary mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. The company's lead therapeutic product candidate is CYP-001, which has completed Phase I clinical trial for the treatment of graft versus host disease. It also develops CYP-004, which is...
Company Valuation
From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks.
Target Price
The average target price of CYP.AX is 0.78 and suggests 102% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to inc
Buy
Sell